FLGT · Insider Trading
Fulgent Genetics, Inc. Common Stock
Every open-market purchase and sale reported by FLGT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-28 | Paul Kim | CFO and Treasurer | F | −2,748 | −$55.56K |
| 2026-10-28 | Hanlin Gao | Chief Scientific Officer | F | −1,645 | −$33.26K |
| 2026-10-28 | Jian Xie | President and COO | F | −4,361 | −$88.18K |
| 2026-09-03 | Hanlin Gao | Chief Scientific Officer | Sell | −1,673 | −$32.89K |
| 2026-09-03 | Jian Xie | President and COO | Sell | −2,127 | −$41.81K |
| 2026-09-03 | Paul Kim | CFO and Treasurer | F | −2,087 | −$40.88K |
| 2026-09-03 | Ming Hsieh | Chief Executive Officer | F | −4,392 | −$86.04K |
| 2026-08-28 | Hanlin Gao | Chief Scientific Officer | Sell | −939 | −$18.69K |
| 2026-08-28 | Jian Xie | President and COO | Sell | −1,193 | −$23.75K |
| 2026-08-28 | Paul Kim | CFO and Treasurer | F | −1,168 | −$23.14K |
| 2026-08-28 | Ming Hsieh | Chief Executive Officer | F | −2,949 | −$58.42K |
| 2026-07-28 | Hanlin Gao | Chief Scientific Officer | F | −1,645 | −$32.36K |
| 2026-07-28 | Jian Xie | President and COO | F | −4,361 | −$85.78K |
| 2026-07-28 | Paul Kim | CFO and Treasurer | F | −2,747 | −$54.03K |
| 2026-06-03 | Hanlin Gao | Chief Scientific Officer | Sell | −1,688 | −$30.19K |
| 2026-06-03 | Paul Kim | CFO and Treasurer | F | −2,087 | −$37.75K |
| 2026-06-03 | Jian Xie | President and COO | Sell | −2,146 | −$38.38K |
| 2026-06-03 | Ming Hsieh | Chief Executive Officer | F | −4,392 | −$79.45K |
| 2026-05-28 | Paul Kim | CFO and Treasurer | F | −1,168 | −$20.64K |
| 2026-05-28 | Jian Xie | President and COO | Sell | −1,201 | −$21.14K |
| 2026-05-28 | Hanlin Gao | Chief Scientific Officer | Sell | −945 | −$16.63K |
| 2026-05-27 | Ming Hsieh | Chief Executive Officer | F | −2,949 | −$52.11K |
| 2026-05-18 | Regina E Groves | Director | A | +11,117 | — |
| 2026-05-18 | Linda Dong | Director | A | +11,117 | — |
| 2026-05-18 | Michael Nohaile | Director | A | +5,558 | — |
| 2026-04-28 | Paul Kim | CFO and Treasurer | F | −2,747 | −$44.80K |
| 2026-04-28 | Jian Xie | President and COO | F | −4,361 | −$71.13K |
| 2026-04-28 | Hanlin Gao | Chief Scientific Officer | F | −1,645 | −$26.83K |
| 2026-03-11 | Ming Hsieh | Chief Executive Officer | J | — | — |
| 2026-03-02 | Hanlin Gao | Chief Scientific Officer | F | −8,325 | −$136.08K |
| 2026-03-02 | Jian Xie | President and COO | F | −10,366 | −$169.66K |
| 2026-03-02 | Paul Kim | CFO and Treasurer | F | −10,648 | −$174.25K |
| 2026-03-02 | Ming Hsieh | Chief Executive Officer | F | −20,515 | −$342.30K |
| 2026-02-25 | Hanlin Gao | Chief Scientific Officer | MIXED | +51,418 | −$362.53K |
| 2026-02-25 | Ming Hsieh | Chief Executive Officer | MIXED | +121,928 | −$1.51M |
| 2026-02-25 | Jian Xie | President and COO | MIXED | +53,641 | −$619.29K |
| 2026-02-25 | Paul Kim | CFO and Treasurer | MIXED | +51,049 | −$633.84K |
| 2026-01-28 | Hanlin Gao | Chief Scientific Officer | F | −1,331 | −$36.64K |
| 2026-01-28 | Paul Kim | CFO and Treasurer | F | −3,004 | −$82.70K |
| 2026-01-28 | Jian Xie | President and COO | F | −4,711 | −$129.69K |
| 2025-12-03 | Paul Kim | CFO and Treasurer | F | −1,131 | −$32.26K |
| 2025-12-03 | Hanlin Gao | Chief Scientific Officer | Sell | −1,075 | −$30.46K |
| 2025-12-03 | Jian Xie | President and COO | Sell | −1,140 | −$32.30K |
| 2025-12-01 | Hanlin Gao | Chief Scientific Officer | Sell | −943 | −$27.88K |
| 2025-12-01 | Paul Kim | CFO and Treasurer | F | −1,166 | −$35.15K |
| 2025-12-01 | Jian Xie | President and COO | Sell | −1,198 | −$35.42K |
| 2025-12-01 | Ming Hsieh | Chief Executive Officer | F | −2,944 | −$88.76K |
| 2025-11-25 | Hanlin Gao | Chief Scientific Officer | Sell | −535 | −$16.30K |
| 2025-11-25 | Paul Kim | CFO and Treasurer | F | −671 | −$20.13K |
| 2025-11-25 | Ming Hsieh | Chief Executive Officer | F | −2,116 | −$63.48K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Hanlin Gao | Chief Scientific Officer | 984,472 | $26.13M |
| Ming Hsieh | Chief Executive Officer | 886,952 | $23.54M |
| Jian Xie | President and COO | 576,379 | $15.30M |
| Paul Kim | CFO and Treasurer | 353,795 | $9.39M |
| Linda Dong | Director | 38,758 | $1.03M |
| Regina E Groves | Director | 28,099 | $745.75K |
| Michael Nohaile | Director | 24,578 | $652.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FLGT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.